Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome.
Rennings
Alexander J
AJ
Department of Pharmacology-Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Evidence Based Practice and Institute for Genetic and Metabolic Disease, PO Box 9101, 6500 HB Nijmegen, The Netherlands. a.rennings@pharmtox.umcn.nl
Meijer
Patrick
P
van Uden
Dominique J
DJ
Tack
Cees J
CJ
Smits
Paul
P
Boerman
Otto C
OC
Oyen
Wim J
WJ
Rongen
Gerard A
GA
D004311:Double-Blind Method; D005542:Forearm / Q000098:blood supply; D006801:Humans; D007333:Insulin Resistance; D007511:Ischemia / Q000000981:diagnostic imaging; D024821:Metabolic Syndrome / Q000150:complications*; D018482:Muscle, Skeletal / Q000098:blood supply; D011877:Radionuclide Imaging; D015427:Reperfusion Injury / Q000517:prevention & control*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone